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ABSTRACT: We here report the synthesis of a series of 12 hybrid
molecules composed of a colchicine moiety and a pironetin analogue
fragment. The two fragments are connected through an ester−amide
spacer of variable length. The cytotoxic activities of these compounds
and their interactions with tubulin have been investigated. Relations
between the structure and activity are discussed. Since the spacer is not
long enough to permit a simultaneous binding of the hybrid molecules
to the colchicine and pironetin sites on tubulin, a further feature
investigated was whether these molecules would interact with the latter
through the pironetin end (irreversible covalent binding) or through the colchicine end (reversible noncovalent binding). It has
been found that binding to tubulin may take place preferentially at either of these ends depending on the length of the
connecting spacer.
■ INTRODUCTION
Cancer, one major health problem in developed countries,1
may be induced by many diﬀerent external and internal causes,
including those of the genetic type. Accordingly, various types
of pharmacological approaches have been explored.2,3 One
involves the use of cytotoxic drugs, which exert their eﬀect
through induction of diﬀerent methods of cell death.4 Many
such drugs owe this property to interaction with the
microtubule network. Microtubules are mainly composed of
αβ-tubulin, a heterodimer formed through noncovalent binding
of its two monomeric constituents. For normal cell function,
microtubules must be dynamic following a process named
microtubule dynamic instability.5 Any molecules which
modulate microtubule dynamics will disrupt the dynamics,
activating checkpoints that block the cell division process, not
only of normal cells but also of tumoral ones. Tubulin-binding
molecules (TBMs) are therefore a class of promising molecules
to design anticancer agents.
TBMs can be classiﬁed depending on the location of their
binding site on either α-tubulin or β-tubulin. Compounds that
bind to β-tubulin are by far more numerous, their eﬀect being
either disruption or stabilization of microtubules. It is
interesting to note that archetypal members of this group
may behave quite diﬀerently: whereas colchicine6 and the Vinca
alkaloids such as vinblastine7 (Figure 1) exert their eﬀects by
inducing disruption of microtubules, paclitaxel causes their
stabilization (and was the ﬁrst-described tubulin-binding drug
found to do so).8 Although their eﬀects are in complete
contrast to one another, all these drugs bind to β-tubulin, albeit
to diﬀerent sites within this protein subunit.5,9,10
Very few products are known to bind to α-tubulin. The ﬁrst-
reported compound to do so was the naturally occurring 5,6-
dihydro-α-pyrone (pironetin).11 It was subsequently discovered
that the peptide-like hemiasterlin family12 (Figure 2) behaves in
the same way. Pironetin, a very potent inhibitor of tubulin
assembly, was found to arrest cell cycle progression in the G2/
M phase.13
Several groups have previously reported structure−activity
relationship (SAR) studies on pironetin. The presence of the
conjugated C2−C3 double bond and of the oxygen atom at C-9
has been shown to be essential for the biological activity. The
presence of a (7R)-hydroxyl group might also be of importance.
It has been suggested that a nucleophilic residue, yet to be
conclusively identiﬁed, of the α-tubulin chain adds in a Michael
fashion to the conjugated double bond of pironetin, therefore
forming a covalent bond with C-3 of the dihydropyrone ring.14
As a ﬁnal remark, the development of new compounds useful
for cancer treatment constitutes a continuous need, due to the
emergence of resistances15 to this therapy, the same
phenomenon previously observed with antibiotics.16
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■ CONCEPT AND DESIGN OF HYBRID
TUBULIN-BINDING LIGANDS
Pironetin is one of the few members of the group of TBMs that
interacts with α-tubulin; thus, it is an interesting target from the
pharmacological point of view. The total synthesis of this
natural compound has been reported several times in the
literature.17 To develop SAR studies, we started three years
ago18 the design of simpliﬁed analogues where all elements that
had not yet proven to be essential for the biological activity
were removed. The initial target structures I and II are
schematically shown in Figure 3.18a On one hand, the
conjugated dihydropyrone ring and the side chain with the
methoxy group at C-9 were maintained. Furthermore, the
hydroxyl group at C-7 was removed in some substrates (I) and
retained in others (II) to see its inﬂuence on the activity. On
the other hand, not only was the isolated C12−C13 double
bond removed, so too were all the alkyl pendants (methyl
groups at C-8 and C-10, ethyl at C-4). We then systematically
varied the conﬁgurations of the two/three remaining stereo-
centers. Proceeding in this way, we prepared all four possible
stereoisomers with general constitution I, with no hydroxyl
group at C-7. Furthermore, we synthesized all eight stereo-
isomers exhibiting general structure II with a hydroxyl group at
C-7.
The cytotoxicity of these analogues and their binding to α/β-
tubulin were then studied. Analogues I and II were found
cytotoxic in the low micromolar range, about 3 orders of
magnitude less active than the parent molecule. As the latter,
they also lead to disruption of the microtubule network.18a
Moreover, no outstanding diﬀerences in cytotoxicity were
observed within stereoisomeric compounds of general structure
I or II, the conﬁgurations of the stereocenters thus apparently
playing a secondary role. Furthermore, we also found that (i)
their behavior in cell cultures resembles that of pironetin, (ii)
they display a biological mechanism of action very similar to
that of this natural compound, and (iii) they compete for the
same binding site in α-tubulin.
As an extension of the project, we decided to synthesize
cytotoxic TBMs with a potential ability to bind to either α- or
β-tubulin and produce a microtubule-destabilizing eﬀect.19
Since this property is characteristic of both pironetin (binds to
α-tubulin) and colchicine (binds to β-tubulin), we decided to
prepare tubulin ligands with a hybrid structure20 such as 1−12
(Figure 4). These molecules display a moiety of colchicine21
and another of the simpliﬁed pironetin type (21, ent-21, and
22; see Schemes 1 and 2), connected in turn by a spacer of
Figure 1. Structures of some natural products reported to selectively
bind to β-tubulin.
Figure 2. Structure of two natural products reported to selectively
bind to α-tubulin.
Figure 3. General structures of simpliﬁed pironetin analogues of the
ﬁrst generation.18a
Figure 4. Structures of the pironetin analogue/colchicine hybrids 1−
12 investigated in this study.
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variable length. The stereocenters of the pironetin moiety in
compounds 9−12 display the same conﬁgurations as in natural
pironetin. Although the two respective binding sites in tubulin
are too far away for these compounds to act as dual ligands,22
this strategy should allow us to explore the relative reactivity of
these two moieties when connected through linkers of various
sizes, as well as the inﬂuence of the chain length.
■ RESULTS AND DISCUSSION
Chemistry. Colchicine was ﬁrst converted into its deacetyl
derivative 13 (Scheme 1) according to a literature procedure.23
N-Acyl derivative 17 was prepared from 13 as reported by
means of treatment with glutaric anhydride.23 Derivatives 18−
20 were prepared through alkaline hydrolysis of methyl esters
14−16, obtained in turn by means of N-acylation of 13 under
the conditions indicated in Scheme 1 (for details, see the
Experimental Section). O-Acylation of the known dihydropyr-
one 2124 with acids 17−20 under Yamaguchi conditions25
aﬀorded the desired compounds 1−4. Compounds 5−8 were
prepared in the same way from dihydropyrone ent-21.24
The hybrid molecules 9−12 were prepared as depicted in
Scheme 2. The known dihydropyrone 2224 was esteriﬁed with
acids 17−20 as above under Yamaguchi conditions. This
yielded compounds 23−26, which were subjected to
desilylation to furnish the desired 9−12.
After synthesis of the hybrid molecules was completed, the
compounds were studied to determine their cytotoxic activity
and their ability to disrupt the microtubule network.
Cytotoxicity Assays. We have carried out a measurement
of the cytotoxicity of compounds 1−12. To do so, IC50
measurements were performed as described in the Exper-
imental Section using two types of tumoral cells, the human
colon adenocarcinoma (HT-29) and the breast adenocarcino-
ma (MCF-7) cell lines. For the sake of comparison, one
nontumoral cell line, the human embryonic kidney cell line
(HEK-293),26 was employed in the assays. The cytotoxicity
values, expressed as the concentration (μmol/L) required to
produce 50% inhibition of cell growth (IC50), are shown in
Table 1 together with the A and B coeﬃcients, obtained by
dividing the IC50 values of the nontumoral cell line (HEK-293)
by those of one or the other tumoral cell line (see footnotes b
and c in the table). The higher the value of the A or B
coeﬃcient, the higher the therapeutic safety margin of the
compound in the corresponding cell line.
The observed IC50 values are in most cases in the medium to
low micromolar range, thus making the compounds 2−3 orders
of magnitude less cytotoxic than either colchicine or pironetin.
For the HT-29 cell line, only compounds 4, 9, 10, and 12
showed a noticeable cytotoxicity in the low micromolar range.
However, the A coeﬃcient was in most cases very low; i.e.,
these compounds were similarly toxic for normal and HT-29
tumoral cells.
The situation was diﬀerent in the case of the MCF-7 cell line,
which showed a much higher sensitivity toward compounds 1−
4, 7, and 8, already in the nanomolar range (IC50 < 1 μM).
Interestingly, the B coeﬃcient was high in some cases (1, 2, and
7), which indicates a better safety margin for these compounds
than in the case of the HT-29 line. However, it is not easy to
draw solid conclusions about the relation between the
structures and the observed cytotoxicity. Within the subsets
of hybrid molecules where there are diﬀerences in the carbon
chain length (e.g., 1−4, 5−8, and 9−12), the IC50 values are
similar and do not show a clear relation with the length of the
carbon chain. No explanation for this fact can be proposed
without knowing whether these compounds are interacting
with tubulin at the pironetin site (irreversible covalent binding
to α-tubulin) or at the colchicine site (reversible noncovalent
binding to β-tubulin). Experiments in this direction will be
discussed below.
Indirect Immunoﬂuorescence and Cell Cycle. To
establish the cellular mechanisms of action of the compounds,
Scheme 1. Synthesis of Pironetin Analogue/Colchicine
Hybrids 1−8a
aReagents and conditions: (a) MeO2C(CH2)nCOOH, DCC, DMAP,
CH2Cl2, 3 h, rt (14, 73%; 15, 82%; 16, 76%); (b) glutaric anhydride,
DMSO, NMM, 45 min, rt (84%); (c) LiOH, aq MeOH, 6 h, rt (18,
64%; 19, 73%; 20, 66%); (d) 17−20, 2,4,6-trichlorobenzoyl chloride,
Et3N, 5 h, rt, then addition of 21 or ent-21, DMAP, 1 h, rt (1, 43%; 2,
50%; 3, 45%; 4, 57%; 5, 44%; 6, 57%; 7, 55%; 8, 54%). Acronyms and
abbreviations: DMAP, 4-(N,N-dimethylamino)pyridine; DCC, dicy-
clohexylcarbodiimide; DMSO, dimethyl sulfoxide; NMM, N-methyl-
morpholine.
Scheme 2. Synthesis of Pironetin Analogue/Colchicine
Hybrids 9−12a
aReagents and conditions: (a) 17−20, 2,4,6-trichlorobenzoyl chloride,
Et3N, 5 h, rt, then addition of 22, DMAP, 1 h, rt (23, 45%; 24, 43%;
25, 55%; 26, 46%); (b) 48% aq HF, MeCN, 3 h, rt (9, 67%; 10, 67%;
11, 74%; 12, 63%).
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we studied their eﬀect on the microtubule cytoskeleton. Among
the 12 available compounds, ligands 1, 3, 9, and 11 were
considered to be appropriate representatives of the whole
group because they diﬀer in the type of pironetin moiety (with
either one or three stereocenters) and/or the length of the
spacer carbon chain (either a short one, n = 3, or a long one, n
= 10). Therefore, we selected them for this and the subsequent
biological experiments. Compounds with the longest carbon
chain (n = 14) were not easy to manipulate because of their
very high hydrophobicity and consequently low solubility. For
that reason, they were not used in these experiments.
Compounds 5−8 were not selected either, because in general
they did not perform better in cytotoxicity than 1−4.
For the study of the eﬀect on the microtubule cytoskeleton,
we used non-small-cell lung adenocarcinoma cells (A-549),27
which were incubated for 24 h in the presence of colchicine and
compounds 1, 3, 9, and 11 (Figure 5). Colchicine at 50 nM
concentration almost completely depolymerizes cellular micro-
tubules (D). Compounds 1 (B) and 11 (F) displayed at 1 μM
concentration a similar eﬀect in microtubule depolymerization;
i.e., they are 20 times less active than colchicine. Compounds 3
(C) and 9 (E) were visibly less active than 1 and 11. In these
preparations, metaphase mitotic cells with type IV mitotic
spindles28 were observed, with the DNA forming a ball without
microtubules (insets in Figure 5). Aberrant mitoses were also
present in all preparations.
We next studied whether compounds 1, 3, 9, and 11 are able
to block A549 cells in the G2/M phase of the cell cycle (Figure
6) in the same way as other microtubule-modulating agents do.
Thus, the cells were incubated for 20 h with the diﬀerent
ligands or the drug vehicle. Colchicine at 50 nM concentration
arrested cells in the G2/M phase almost completely. All four
compounds 1, 3, 9, and 11 caused a similar eﬀect at
concentrations in the low micromolar range (≤10 μM), with
11 being somewhat more active. We may thus conclude that,
although less cytotoxic than colchicine, these hybrid molecules
also perturb the microtubular network and cause mitotic arrest
in the G2/M phase (more than 80% of the cells are in this
phase of the cell cycle).
Inhibition of Microtubule Assembly. The conﬁrmation
of cellular microtubule assembly inhibition activity by
compounds 1, 3, 9, and 11 led us to study their ability to
inhibit puriﬁed tubulin microtubule assembly. We wished to
know whether the activity is exerted by tubulin binding in the
way pironetin does or in the way colchicine does. To do so, the
Table 1. Cytotoxicity of Pironetin Analogue/Colchicine Hybrids 1−12 toward Two Tumoral (HT-29 and MCF-7) Cell Lines
and One Normal (HEK-293) Cell Linea
drug HT-29 MCF-7 HEK-293 Ab Bc
colchicine 0.050 ± 0.003 0.012 ± 0.007 0.005 ± 0.001 0.1 0.4
pironetin 0.0064 ± 0.0007 0.006 ± 0.002 0.017 ± 0.001 2.6 2.8
1 21 ± 6 0.7 ± 0.2 6 ± 2 0.3 8.7
2 20 ± 8 0.29 ± 0.24 33 ± 4 1.6 >100
3 18 ± 3 0.33 ± 0.18 1.40 ± 0.95 <0.1 4.2
4 8 ± 5 0.6 ± 0.3 0.44 ± 0.09 <0.1 0.7
5 65 ± 15 19 ± 1 0.4 ± 0,3 <0.1 <0.1
6 40 ± 6 12 ± 5 0.7 ± 0.2 <0.1 <0.1
7 40 ± 6 0.3 ± 0.2 24 ± 10 0.6 80
8 30 ± 19 0.5 ± 0.1 0.5 ± 0.1 <0.1 1
9 7 ± 1 36 ± 7 14 ± 3 2 0.4
10 3.8 ± 0.7 9 ± 3 7 ± 1 1.8 0.7
11 31 ± 11 60 ± 1 3.8 ± 0.6 0.1 <0.1
12 1.4 ± 0.8 28 ± 0.1 2 ± 1 1.6 <0.1
aIC50 values, which include those of the parent compounds colchicine and pironetin, are expressed as the compound concentration (μmol/L or μM)
that causes 50% inhibition of cell growth. The values are the average (±SD) of three diﬀerent measurements performed as described in the
Experimental Section. bA = IC50(HEK-293)/IC50(HT-29).
cB = IC50(HEK-293)/IC50(MCF-7).
Figure 5. Eﬀect of hybrid compounds 1, 3, 9, and 11 as compared to
colchicine on the microtubule network and the nucleus morphology.
A549 cells were incubated for 24 h with drug vehicle DMSO (A), 1
μM 1 (B), 5 μM 3 (C), 50 nM colchicine (D), 20 μM 9 (E), and 1 μM
11 (F). Microtubules were stained with α-tubulin antibodies, whereas
DNA was stained with Hoechst 33342. Insets are mitotic spindles from
the same preparation. The scale bar (F) represents 10 μm. All panels
and insets have the same magniﬁcation.
Figure 6. Cell cycle histograms of A549 lung carcinoma cells untreated
(control) or treated with colchicine and compounds 1, 3, 9, and 11.
The lowest ligand concentration that induces maximal arrest in the
G2/M phase is depicted.
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critical concentration29 required for tubulin assembly was
determined in glycerol-assembling buﬀer (GAB) in the
presence of an excess (30 μM) of compounds 1, 3, 9, and
11. Indeed, the concentration of tubulin required to produce
assembly increases from 3.30 ± 0.10 μM in the absence of
ligands (DMSO vehicle) to a maximum value of 6.6 ± 1.1 μM
in their presence, the latter being shown by compound 1
(Table 2). The other compounds (3, 9, and 11) showed
slightly lower values of the critical concentration, but it is
anyway clear that all four ligands inhibit microtubule assembly.
For the sake of comparison, the values measured for docetaxel
(a microtubule-stabilizing agent), colchicine, and pironetin have
been included. The values measured for the hybrid molecules
conﬁrm therefore that the observed eﬀect in cells is due to their
interaction with tubulin.
Mechanisms of Interaction of the Hybrid Molecules
with Tubulin. With the idea of acquiring a more detailed view
of the binding mechanism of these hybrid molecules, the eﬀect
of compounds 1, 3, 9, and 11 on A2780 and A2780AD human
ovarian carcinoma cells30 was investigated. A2780 cells are
sensitive to chemotherapy, whereas A2780AD cells have
acquired resistance by means of P-glycoprotein overexpression.
Thus, we determined the IC50 values of the aforementioned
compounds and compared them with those measured for
pironetin and colchicine (Table 3). Pironetin is active in the
low nanomolar range with similar values in both the parental
and resistant cell lines, as expected for a compound with a
mechanism of action based on covalent binding to its target.30
Colchicine is also cytotoxic in the low nanomolar range for the
sensitive line, but the IC50 value for the resistant line was
noticeably higher (RF > 20), in accordance with that expected
for a noncovalent binding mode. Table 3 shows that
compounds 1, 3, 9, and 11 are also very cytotoxic, most
particularly 1, 3, and 11 (IC50 = 500, 240, and 400 nM,
respectively), but it is also worth mentioning that these four
compounds exhibit high RF values, a feature which would
suggest that they are binding to tubulin through a noncovalent
mode. However, the large hydrophobic spacer may turn the
substrates into good substrates for the P-glycoprotein. Since
this would favor the resistance mechanism in the A2780AD
cells, binding through the pironetin site cannot be discarded on
the basis of these data alone.
To deepen our understanding of these interaction mecha-
nisms, we have carried out measurements of the responses of
tubulin critical concentration to changes in the concentrations
of ligands. The results in the speciﬁc case of compound 11 and
colchicine are shown in Table 4. In principle, a diﬀerent
dependence of the inhibition of microtubule assembly on the
ligand concentration would be expected depending on the way
the ligand reacts with tubulin. On one hand, pironetin reacts
covalently with the α subunit in the interdimer interface, where
it will inhibit the addition of the modiﬁed tubulin dimer.13d The
net result is a decrease of the concentration of free tubulin
dimers available to bind to the microtubule end in a
stoichiometric way. On the other hand, colchicine binds in
the intradimer interface with the result of a change in the
geometry of the dimer.31 This modiﬁed dimer actually binds to
the microtubule end but prevents the addition of further
dimers, thus acting as a mitotic poison. Furthermore, dimers
modiﬁed in this way are able to assemble with formation of a
polymer with a diﬀerent geometry. This implies that colchicine
and its derivatives act at substoichiometric concentrations
whereas pironetin acts in a stoichiometric way. As a
consequence, for pironetin-type ligands, a continuous incre-
ment in the critical concentration required for assembly has to
be expected when the drug concentration increases, leading to a
nonassembly system when the pironetin concentration is
stoichiometric with tubulin (all tubulin is unable to assembly).
In contrast, a stabilization of the critical concentration
measured would be expected for colchicine site ligands, when
overstoichiometric concentrations are reached.
The observed results do not allow us to clearly distinguish
between a stoichiometric type of inhibition (pironetin-like) and
a poison type of inhibition (colchicine-like). This is probably
due to the lower potency of the hybrid compounds as
Table 2. Critical Concentration (CrC) for the Assembly of
Puriﬁed Tubulin in GAB Proteins in the Presence of the
Hybrid Ligandsa
compd CrC (μM) compd CrC (μM)
DMSO 3.30 ± 0.10 1 6.6 ± 1.1
docetaxel 0.9 ± 0.2 3 6.3 ± 0.7
pironetin >15 9 5.3 ± 0.1
colchicine >15 11 5.7 ± 0.3
aThe concentration is 25 μM for docetaxel, colchicine, and pironetin
and 30 μM for compounds 1, 3, 9, and 11. Data are the average of
three measurements. Errors (SD) are standard errors of the average.
The tubulin concentration is 20 μM in all experiments.
Table 3. Cytotoxicity of Several Selected Compounds toward
Ovarian Carcinoma Cells Sensitive (A2780) and Resistant
(A2780AD) to Chemotherapya
drug A2780 A2780AD RFb
colchicine 0.015 ± 0.002 0.306 ± 0.34 >20
pironetin 0.008 ± 0.001 0.025 ± 0.002 ∼3
1 0.5 ± 0.001 59 ± 10 118
3 0.24 ± 0.002 26.5 ± 0.4 110
9 1.9 ± 0.1 >100 >50
11 0.4 ± 0.002 14.8 ± 0.1 ∼37
aIC50 values, which include those of the parent compounds colchicine
and pironetin, are expressed as the compound concentration (μmol/L
or μM) that causes 50% inhibition of cell growth. The values are the
average (±SD) of three diﬀerent measurements performed as
described in the Experimental Section. bResistance factor, obtained
by dividing the IC50 of the A2780AD cell line by that of the parental
A2780 line.
Table 4. Responses of the CrC Values to Changes in the
Concentrations of Colchicine and Compound 11a
compd 11 colchicine
concn (μM) CrC (μM) concn (μM) CrC (μM)
DMSO (control) 3.3 ± 0.1 DMSO (control) 3.3 ± 0.1
0.1 3.4 ± 0.1 0.1 3.3 ± 0.1
0.5 3.5 ± 0.1 0.5 3.9 ± 0.1
1 4.0 ± 0.1 1 4.3 ± 0.1
5 4.5 ± 0.3 5 6.6 ± 0.7
10 5.9 ± 0.1 10 12.9 ± 1.0
30 5.7 ± 0.3 30 13.7 ± 3.3
aData are the average of three measurements. Errors (SD) are
standard errors of the average. The tubulin concentration is 20 μM in
all experiments.
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compared with the parent compounds colchicine and pironetin.
However, since the behavior of compound 11 at over-
stoichiometric concentrations (30 μM for 20 μM tubulin)
resembles that of colchicine, i.e., a stabilization of the critical
concentration observed, it could perhaps be concluded that this
compound binds to tubulin through the colchicine moiety.
However, a more decisive conclusion is still lacking.
To check the binding mechanisms by means of another
additional method, we investigated the direct interaction of
ligands 1, 3, 9, and 11 with tubulin. The method used was
related to that employed in our former study18a to determine
whether our analogues did actually compete with pironetin for
binding to tubulin. Thus, we allowed each of the four
compounds at 30 μM concentration to interact with tubulin
at the same concentration and then extracted the solution with
an organic solvent (see the Experimental Section for details).
We then analyzed the fraction of the ligand (solution A) which
was extracted with the solvent. Since interaction at the
pironetin analogue side is expected to irreversibly lead to a
covalent bond with tubulin, the corresponding molecules will
not be extracted with the organic solvent. In contrast,
interaction at the colchicine side is expected to lead to the
reversible formation of a noncovalent bond, whereby the
corresponding molecules will be extracted with the solvent.
In a second experiment, each of the four compounds at 30
μM concentration was allowed to interact as above with
tubulin. After allowing for microtubule assembly, the
suspension was ultracentrifuged, and the supernatant solution
was separated from the solid pellet. Then both the solution and
the pellet were separately extracted with the organic solvent.
Material extracted from the supernatant solution (solution B)
contains molecules that have not interacted with tubulin,
whereas material extracted from the pellet (solution C)
contains molecules that have interacted with tubulin in a
noncovalent mode (colchicine end). Obviously, molecules that
have become covalently bound to tubulin (pironetin end)
remain in the pellet but are not extracted with the solvent.
Examination of the values in Table 5 suggests that
compounds 1 and 9 interact only weakly with tubulin at the
pironetin end, as indicated by the fact that most of the
respective compound remains in solution A. The presence of
the same compounds in low concentration in solution C
indicates that some interaction, although not a strong one, has
taken place at the colchicine end. As regards compounds 3 and
11, they display a strong interaction at the pironetin end, most
particularly 3, as shown by the fact that only a small percentage
of the respective compound remains in solution A. Both
compounds also show interaction at the colchicine end with an
intensity similar to that of the other two.
The aforementioned results have to be considered in light of
the structures of the corresponding compounds. On one hand,
molecules of compounds 1 and 9, which interact weakly with
tubulin through the pironetin end, display a short spacer
between the latter and the colchicine end. It is thus possible
that because of the steric bulk of the colchicine “tail”, the
molecule experiences a marked kinetic hurdle to penetrate
through the binding channel at the pironetin site in α-tubulin.
That the interaction with the colchicine end is also weak may
possibly be due to the size of the N-acyl residue. Indeed, it has
been reported that the activity of N-acyl derivatives of
colchicine is dependent on the size of the substituent, with
larger N-acyl residues giving rise to lower activities.32 On the
other hand, molecules of compounds 3 and 11, which display a
much longer spacer between the pironetin and the colchicine
ends, do not ﬁnd high steric barriers imposed by the now
remote colchicine tail. As a result, they can covalently bind to
the pironetin site. In any case, we cannot discard the alternative
possibility that compound 3, which has the simplest pironetin
chain and is thus structurally much more distant from this
natural product, is actually interacting covalently in a
nonselective way with some unspeciﬁed nucleophilic residue
of the protein chain not situated at the pironetin binding site.
The results presented above are worth discussing. While
some of the data, such as the CrC values in Table 4 and most
particularly the high RF values in Table 3, point to ligand−
tubulin interactions taking place through the colchicine end,
even though weakly, those of Table 5 indicate that binding may
occur mainly at the pironetin end, provided that the length of
the spacer is appropriate. A possible explanation for this
discrepancy is related to the structures of ligands 1−12. Half of
the structure corresponds to an essentially unchanged
colchicine moiety, whereas the other half displays a markedly
simpliﬁed pironetin fragment. Our previous results18 have
shown that even minor modiﬁcations (deletions in our cases)
of the pironetin moiety lead to decreases of the cytotoxic
activity of about 2−3 orders of magnitude. Therefore, it is likely
that the low cytotoxicities measured for compounds 1−12 with
the cell lines in Table 1 are due mainly to the colchicine part,
which interacts through the noncovalent mode. The responses
of the CrC values to changes in concentrations (Table 4) point
in the same direction. Covalent interactions though the
pironetin end, such as those possibly occurring in molecules
such as 3 and 11 (Table 5), are irreversible but may also be
kinetically much slower than in the case of pironetin itself. In
such a situation, the eﬄux mechanism mediated by the P-
glycoprotein may have enough time to extrude the molecules in
the case of resistant cells, therefore explaining the high RF
values in Table 3.
■ CONCLUSION
We have prepared a set of synthetic hybrid molecules 1−12
containing a colchicine moiety and a fragment structurally
related to the natural product pironetin. The two structural
moieties have been connected through a spacer of variable
length containing an ester and an amide group. The spacer was
not long enough to permit simultaneous interaction of the
molecules with the colchicine and the pironetin sites; thus,
competitive binding was expected to take place. The cytotoxic
activities of all these compounds and the interactions of some
of them with tubulin have been investigated. While the tested
compounds showed lower cytotoxicity values than the parental
molecules colchicine and pironetin, we have found that the
Table 5. Interaction of Compounds 1, 3, 9, and 11 with
Tubulin at Equimolecular Concentration
concna (μM)
compd solution A solution B solution C
1 21.7 18.1 5.7
3 6.9 2.0 5.7
9 28.5 20.5 4.7
11 12.8 7.3 3.4
aConcentration of the respective compound in the corresponding
extract (reference solution in the absence of tubulin, 30 μM).
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binding of the compounds to tubulin is strongly inﬂuenced by
the length of the connecting spacer. These results have been
interpreted on the assumption that, if the distance between the
pironetin and the colchicine ends is small (short spacer), the
sterically bulky colchicine moiety hinders the hybrid molecules
from arriving at the pironetin binding site. Consequently,
reversible binding at the colchicine site takes place, even if with
reduced activity. For longer spacers, steric hindrance to enter
the pironetin site is lower, and the molecules may be able to
bind covalently at that site.
■ EXPERIMENTAL SECTION
General Chemistry Methods. NMR spectra were measured at 25
°C. The signals of the deuterated solvent (CDCl3) were taken as the
reference. Multiplicity assignments of 13C signals were made by means
of the DEPT pulse sequence. Complete signal assignments in 1H and
13C NMR spectra with the aid of 2D homo- and heteronuclear pulse
sequences (COSY, HSQC, HMBC) have been performed only for
compounds 14 and 25. In the remaining spectra, signals were assigned
on the basis of the structural similarity (the positions and shapes of the
NH signals have been found to vary to a marked extent depending on
the concentration of the sample and perhaps also on the presence of
water traces in the deuterated solvent). Electrospray high-resolution
mass spectra (ESMS) were measured in the positive ion mode. IR data
were measured with oily ﬁlms on NaCl plates (oils) or KBr pellets
(solids) and are given only for molecules with relevant functional
groups (OH, CO). Optical rotations were measured at 25 °C.
Experiments which required an inert atmosphere were carried out
under dry N2 in ﬂame-dried glassware. Et2O and THF were freshly
distilled from sodium/benzophenone ketyl and transferred via syringe.
Dichloromethane was freshly distilled from CaH2. Tertiary amines
were freshly distilled from KOH. Commercially available reagents were
used as received. Unless detailed otherwise, “workup” means pouring
the reaction mixture into brine, followed by extraction with the solvent
indicated in parentheses. If the reaction medium was acidic (basic), an
additional washing with 5% aq NaHCO3 (aq NH4Cl) was performed.
New washing with brine, drying over anhydrous Na2SO4, and
elimination of the solvent under reduced pressure were followed by
chromatography on a silica gel column (60−200 μm) with the
indicated eluent. Where solutions were ﬁltered through a Celite pad,
the pad was additionally washed with the same solvent used, and the
washings were incorporated into the main organic layer. The samples
of compounds used for the biological studies were puriﬁed to >95% by
means of preparative HPLC.
N-Acylation of Deacetylcolchicine (13) to Amide Esters 14−
16 (Reaction Conditions a in Scheme 1). 13 (358 mg, ca. 1 mmol)
and the appropriate diacid monomethyl ester (1.5 mmol) were
dissolved under N2 in dry CH2Cl2 (75 mL) and treated with DCC
(1.55 g, 7.5 mmol) and DMAP (367 mg, 3 mmol). The mixture was
then stirred for 3 h at room temperature and then ﬁltered through
Celite. The ﬁltrate was evaporated under reduced pressure, and the
residue was subjected to column chromatography on silica gel
(CH2Cl2−MeOH, 98:2) to aﬀord the desired compound 14−16.
For individual yields, see Scheme 1.
N-Acylation of 13 to Amide Acid 17 (Reaction Conditions b
in Scheme 1). The reaction was performed under the reported
conditions:23 13 (358 mg, 1 mmol) was dissolved under N2 in dry
DMSO (2 mL) and treated with glutaric anhydride (125 mg, 1.1 mol)
and N-methylmorpholine (440 μL, 4 mmol). After being stirred at
room temperature for 45 min, the reaction mixture was worked up
(extraction with EtOAc). Column chromatography on silica gel
(CH2Cl2−MeOH, 9:1) aﬀorded compound 17 in 84% yield (yield and
spectral data were not given in ref 23).
Alkaline Hydrolysis of Esters 14−16 to Acids 18−20
(Reaction Conditions c in Scheme 1). The appropriate ester
14−16 (2 mmol) was dissolved in MeOH (5 mL) at room
temperature. After addition of a 5 M aqueous solution of NaOH (2
mL, 10 mmol), the reaction mixture was stirred for 8 h at room
temperature. Workup (extraction with EtOAc) was followed by
column chromatography of the oily residue on silica gel (CH2Cl2−
MeOH, 9:1) to aﬀord the desired acid 18−20. For individual yields,
see Scheme 1.
Yamaguchi Esteriﬁcation of Acids 17−20 with Pyrone
Alcohol 21, ent-21, or 22 (Reaction Conditions d in Scheme
1 and a in Scheme 2). The appropriate acid 17−20 (0.5 mmol) was
dissolved under N2 in dry CH2Cl2 (10 mL) and treated sequentially
with Et3N (210 μL, 1.5 mmol) and 2,4,6-trichlorobenzoyl chloride
(160 μL, ca. 1 mmol). The mixture was then stirred at room
temperature for 5 h. Subsequently, a solution of the required alcohol
21, ent-21, or 22 (1 mmol) and DMAP (122 mg, 1 mmol) in dry
CH2Cl2 (5 mL) was added dropwise. The mixture was then further
stirred at room temperature for 30 min. Workup (extraction with
CH2Cl2) was followed by column chromatography of the oily residue
on silica gel (ﬁrst hexane−EtOAc (1:4), then CH2Cl2−MeOH
(98:2)). This provided the desired esters 1−8 and 23−26. For
individual yields, see Scheme 2.
Acid-Catalyzed Desilylation of Compounds 23−26 to 9−12
(Reaction Conditions b in Scheme 2). The appropriate silylated
compound (0.2 mmol) was dissolved in MeCN (2 mL) and treated
with 48% aq HF (84 μL, ca. 2 mmol). The mixture was then stirred at
room temperature for 3 h, cooled, and neutralized by addition of solid
NaHCO3. After ﬁltration, the solution was evaporated under reduced
pressure, and the oily residue was subjected to column chromatog-
raphy on silica gel (EtOAc−MeOH, 6:4) to yield the desired
desilylated compound. For individual yields, see Scheme 2.
Compounds are described in numerically increasing order.
Data for 5-[(2R)-6-oxo-3,6-dihydro-2H-pyran-2-yl]pentyl 5-
oxo-5 - { ( 7S ) -1 ,2 ,3 ,10 - te t ramethoxy -9 -oxo-5 ,6 , 7 , 9 -
tetrahydrobenzo[a]heptalen-7-yl)amino}pentanoate (1): oil;
[α]D −123.7 (c 0.79, CHCl3); 1H NMR (500 MHz) δ 7.43 (1H, s),
7.42 (1H, br s, NH), 7.26 (1H, d, J = 10.7 Hz), 6.85 (1H, ddd, J = 9.7,
5.4, 3 Hz), 6.81 (1H, d, J = 10.7 Hz), 6.50 (1H, s), 5.98 (1H, ddd, J =
9.7, 2.5, 1.5 Hz), 4.60 (1H, m), 4.41 (1H, m), 4.00 (2H, t, J = 6.6 Hz),
3.97 (3H, s), 3.90 (3H, s), 3.87 (3H, s), 3.63 (3H, s), 2.48 (1H, br dd,
J ≈ 13.3, 6.3 Hz), 2.40−2.20 (8H, br m), 1.90−1.70 (4H, br m), 1.65−
1.30 (7H, br m); 13C NMR (125 MHz) δ 179.4, 173.1, 171.8, 164.5,
163.9, 153.4, 151.6, 151.1, 141.6, 136.4, 134.1, 125.6 (C), 145.1, 135.1,
130.6, 121.4, 112.3, 107.3, 77.7, 52.1 (CH), 64.1, 36.6, 34.9, 34.6, 33.5,
29.8, 29.2, 28.3, 25.6, 24.3, 20.6 (CH2), 61.4, 61.2, 56.2, 56.0 (CH3);
IR νmax 3300 br (NH), 1729 br, 1672 (CO) cm−1; HR ESMS m/z
638.2969 (M + H+), calcd for C35H44NO10, 638.2965.
Data for 5-[(2R)-6-oxo-3,6-dihydro-2H-pyran-2-yl]pentyl 8-
oxo-8 - { ( 7S ) -1 ,2 ,3 ,10 - te t ramethoxy -9 -oxo-5 ,6 , 7 , 9 -
tetrahydrobenzo[a]heptalen-7-yl)amino}octanoate (2): oil;
[α]D −136.8 (c 1.3, CHCl3); 1H NMR (500 MHz) δ 7.80 (1H, br
d, J ≈ 7 Hz, NH), 7.42 (1H, s), 7.21 (1H, d, J = 10.7 Hz), 6.79 (2H,
m), 6.44 (1H, s), 5.90 (1H, br d, J ≈ 9.8 Hz), 4.54 (1H, m), 4.34 (1H,
m), 3.94 (2H, t, J = 6.7 Hz), 3.90 (3H, s), 3.84 (3H, s), 3.80 (3H, s),
3.57 (3H, s), 2.42 (1H, br dd, J ≈ 13.1, 6 Hz), 2.30−2.10 (7H, br m),
1.80 (1H, m), 1.69 (1H, m), 1.60−1.40 (8H, br m), 1.40−1.20 (8H, br
m); 13C NMR (125 MHz) δ 179.1, 173.4, 172.6, 164.3, 163.7, 153.1,
152.0, 150.9, 141.3, 136.4, 134.0, 125.4 (C), 145.1, 135.0, 130.4, 120.9,
112.3, 107.1, 77.5, 52.0 (CH), 63.7, 36.2, 35.6, 34.4, 33.9, 29.6, 29.0,
28.6, 28.4, 28.2, 25.4, 24.9, 24.4, 24.1 (CH2), 61.2, 61.0, 56.1, 55.8
(CH3); IR νmax 3300 br (NH), 1725 br, 1674 (CO) cm−1; HR
ESMS m/z 680.3436 (M + H+), calcd for C38H50NO10, 680.3435.
Data for 5-[(2R)-6-oxo-3,6-dihydro-2H-pyran-2-yl]pentyl 12-
oxo-12- { (7S ) -1 ,2 ,3 ,10- tet ramethoxy-9-oxo-5 ,6 ,7 ,9 -
tetrahydrobenzo[a]heptalen-7-yl)amino}dodecanoate (3): oil;
[α]D −52 (c 1.4, CHCl3); 1H NMR (500 MHz) δ 7.45 (2H, br s), 7.26
(1H, d, J = 10.7 Hz), 6.82 (1H, overlapped m), 6.80 (1H, d, J = 10.7
Hz), 6.49 (1H, s), 5.97 (1H, br d, J ≈ 9.8 Hz), 4.60 (1H, m), 4.39
(1H, m), 4.01 (2H, t, J = 6.6 Hz), 3.95 (3H, s), 3.89 (3H, s), 3.84 (3H,
s), 3.60 (3H, s), 2.46 (1H, br dd, J ≈ 13.2, 6.4 Hz), 2.35−2.10 (7H, br
m), 1.85−1.70 (2H, m), 1.65−1.40 (8H, br m), 1.40−1.20 (16H, br
m); 13C NMR (125 MHz) δ 179.3, 173.7, 172.8, 164.3, 163.8, 153.3,
151.9, 151.0, 141.5, 136.5, 134.1, 125.6 (C), 145.0, 135.0, 130.5, 121.2,
112.4, 107.3, 77.7, 52.0 (CH), 63.9, 36.5, 36.0, 34.6, 34.2, 29.8, 29.3
(×2), 29.2 (×2), 29.1, 29.0, 28.9, 28.4, 25.6, 25.2, 24.9, 24.3 (CH2),
61.4, 61.2, 56.2, 55.9 (CH3); IR νmax 3300 br (NH), 1725 br, 1672
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(CO) cm−1; HR ESMS m/z 736.4056 (M + H+), calcd for
C42H58NO10, 736.4061.
Data for 5-[(2R)-6-oxo-3,6-dihydro-2H-pyran-2-yl]pentyl 16-
oxo-16- { (7S ) -1 ,2 ,3 ,10- tet ramethoxy-9-oxo-5 ,6 ,7 ,9 -
tetrahydrobenzo[a]heptalen-7-yl)amino}hexadecanoate (4):
oil; [α]D −88.7 (c 1.4, CHCl3); 1H NMR (500 MHz) δ 7.45 (1H,
s), 7.28 (1H, d, J = 10.7 Hz), 7.20 (1H, br d, J ≈ 7 Hz, NH), 6.86 (1H,
ddd, J = 9.8, 5.5, 3.5 Hz), 6.81 (1H, d, J = 10.7 Hz), 6.50 (1H, s), 5.99
(1H, br d, J ≈ 9.8 Hz), 4.62 (1H, m), 4.40 (1H, m), 4.03 (2H, t, J =
6.6 Hz), 3.97 (3H, s), 3.91 (3H, s), 3.87 (3H, s), 3.62 (3H, s), 2.48
(1H, br dd, J ≈ 13.6, 6.3 Hz), 2.40−2.15 (7H, br m), 1.85−1.70 (2H,
m), 1.65−1.50 (10H, br m), 1.45−1.20 (22H, br m); 13C NMR (125
MHz) δ 179.3, 173.7, 172.9, 164.3, 163.8, 153.3, 151.9, 151.0, 141.5,
136.5, 134.1, 125.6 (C), 145.0, 135.0, 130.5, 121.2, 112.4, 107.3, 77.7,
52.0 (CH), 63.9, 36.5, 36.0, 34.6, 34.2, 29.8, 29.4 (×5), 29.3 (×4),
29.1, 29.0, 28.4, 25.6, 25.3, 24.9, 24.3 (CH2), 61.4, 61.2, 56.2, 56.0
(CH3); IR νmax 3300 br (NH), 1731 br, 1672 (CO) cm−1; HR
ESMS m/z 792.4691 (M + H+), calcd for C46H66NO10, 792.4687.
Data for 5-[(2S)-6-oxo-3,6-dihydro-2H-pyran-2-yl]pentyl 5-
oxo -5 - { (7S ) - 1 , 2 , 3 ,10 - te t ramethoxy -9 -oxo -5 ,6 , 7 , 9 -
tetrahydrobenzo[a]heptalen-7-yl)amino}pentanoate (5): oil;
[α]D −54.7 (c 1.24, CHCl3); 1H NMR (500 MHz) δ 7.66 (1H, br
d, J ≈ 7 Hz, NH), 7.40 (1H, s), 7.22 (1H, d, J = 10.7 Hz), 6.81 (1H,
overlapped m), 6.79 (1H, d, J = 10.7 Hz), 6.46 (1H, s), 5.91 (1H, br d,
J ≈ 9.8 Hz), 4.55 (1H, m), 4.34 (1H, m), 3.94 (2H, t, J = 6.6 Hz), 3.92
(3H, s), 3.85 (3H, s), 3.81 (3H, s), 3.58 (3H, s), 2.44 (1H, br dd, J ≈
13.3, 6.2 Hz), 2.30−2.10 (7H, br m), 1.85−1.65 (4H, br m), 1.60−
1.25 (8H, br m); 13C NMR (125 MHz) δ 179.2, 172.9, 171.8, 164.4,
163.7, 153.2, 151.7, 150.9, 141.4, 136.3, 134.1, 125.4 (C), 145.1, 135.0,
130.4, 121.0, 112.3, 107.2, 77.7, 52.0 (CH), 63.9, 36.3, 34.6, 34.4, 33.3,
29.7, 29.1, 28.1, 25.5, 24.2, 20.4 (CH2), 61.2, 61.0, 56.1, 55.9 (CH3);
IR νmax 3300 br (NH), 1722 br, 1672 (CO) cm−1; HR ESMS m/z
638.2969 (M + H+), calcd for C35H44NO10, 638.2965.
Data for 5-[(2S)-6-oxo-3,6-dihydro-2H-pyran-2-yl]pentyl 8-
oxo -8 - { (7S ) - 1 , 2 , 3 ,10 - te t ramethoxy -9 -oxo -5 ,6 , 7 , 9 -
tetrahydrobenzo[a]heptalen-7-yl)amino}octanoate (6): oil;
[α]D −69.8 (c 0.8, CHCl3); 1H NMR (500 MHz) δ 7.46 (1H, s),
7.43 (1H, br d, J ≈ 7 Hz, NH), 7.27 (1H, d, J = 10.7 Hz), 6.84 (1H,
ddd, J = 9.7, 5.4, 3 Hz), 6.81 (1H, d, J = 10.7 Hz), 6.50 (1H, s), 5.97
(1H, br dt, J ≈ 9.8, 2 Hz), 4.60 (1H, m), 4.38 (1H, m), 4.00 (2H, t, J =
6.6 Hz), 3.96 (3H, s), 3.89 (3H, s), 3.85 (3H, s), 3.61 (3H, s), 2.47
(1H, br dd, J ≈ 13.4, 6 Hz), 2.40−2.10 (7H, br m), 1.84 (1H, m), 1.75
(1H, m), 1.65−1.45 (8H, br m), 1.40−1.20 (8H, br m); 13C NMR
(125 MHz) δ 179.3, 173.6, 172.6, 164.4, 163.8, 153.3, 151.8, 151.0,
141.5, 136.5, 134.1, 125.6 (C), 145.1, 135.0, 130.6, 121.2, 112.4, 107.3,
77.7, 52.0 (CH), 63.9, 36.5, 35.8, 34.6, 34.0, 29.8, 29.2, 28.8, 28.6, 28.4,
25.6, 25.1, 24.6, 24.3 (CH2), 61.4, 61.2, 56.2, 56.0 (CH3); IR νmax 3300
br (NH), 1721 br, 1674 (CO) cm−1; HR ESMS m/z 680.3433 (M
+ H+), calcd for C38H50NO10, 680.3435.
Data for 5-[(2S)-6-oxo-3,6-dihydro-2H-pyran-2-yl]pentyl 12-
oxo-12- { (7S ) -1 ,2 ,3 ,10- tet ramethoxy-9-oxo-5 ,6 ,7 ,9 -
tetrahydrobenzo[a]heptalen-7-yl)amino}dodecanoate (7): oil;
[α]D −22.2 (c 1.1, CHCl3); 1H NMR (500 MHz) δ 7.45 (1H, s), 7.30
(1H, d, J = 10.7 Hz), 6.88 (1H, ddd, J = 9.8, 5.4, 3 Hz), 6.85 (1H, d, J
= 10.7 Hz), 6.70 (1H, br d, J ≈ 7 Hz, NH), 6.50 (1H, s), 6.01 (1H, br
d, J ≈ 9.8 Hz), 4.62 (1H, m), 4.42 (1H, m), 4.04 (2H, t, J = 6.6 Hz),
3.98 (3H, s), 3.90 (3H, s), 3.86 (3H, s), 3.63 (3H, s), 2.46 (1H, br dd,
J ≈ 13.2, 6.7 Hz), 2.40−2.10 (7H, br m), 1.83 (1H, m), 1.65−1.40
(9H, br m), 1.40−1.20 (16H, br m); 13C NMR (125 MHz) δ 179.4,
173.9, 172.7, 164.4, 164.0, 153.4, 151.3, 151.2, 141.7, 136.3, 134.1,
125.7 (C), 145.0, 135.0, 130.7, 121.4, 112.3, 107.4, 77.8, 52.0 (CH),
64.0, 36.9, 36.3, 34.6, 34.7, 34.3, 34.0, 29.4, 29.3−29.0 (ﬁve partially
overlapped signals), 28.5, 25.7, 25.4, 25.0, 24.5 (CH2), 61.5, 61.3, 56.3,
56.1 (CH3); IR νmax 3300 br (NH), 1734 br, 1671 (CO) cm−1; HR
ESMS m/z 736.4062 (M + H+), calcd for C42H58NO10, 736.4061.
Data for 5-[(2S)-6-oxo-3,6-dihydro-2H-pyran-2-yl]pentyl 16-
oxo-16- { (7S ) -1 ,2 ,3 ,10- tet ramethoxy-9-oxo-5 ,6 ,7 ,9 -
tetrahydrobenzo[a]heptalen-7-yl)amino}hexadecanoate (8):
oil; [α]D −25.2 (c 1.9, CHCl3); 1H NMR (500 MHz) δ 7.46 (1H,
s), 7.45 (1H, br d, J ≈ 7 Hz, NH), 7.28 (1H, d, J = 10.7 Hz), 6.84 (1H,
ddd, J = 9.8, 5.4, 3 Hz), 6.82 (1H, d, J = 10.7 Hz), 6.49 (1H, s), 5.98
(1H, br d, J ≈ 9.8 Hz), 4.62 (1H, m), 4.38 (1H, m), 4.02 (2H, t, J =
6.6 Hz), 3.96 (3H, s), 3.90 (3H, s), 3.86 (3H, s), 3.62 (3H, s), 2.46
(1H, br dd, J ≈ 13.6, 6.4 Hz), 2.40−2.15 (7H, br m), 1.85−1.70 (2H,
m), 1.65−1.50 (9H, br m), 1.40−1.20 (24H, br m); 13C NMR (125
MHz) δ 179.3, 173.7, 172.9, 164.3, 163.8, 153.3, 151.9, 151.0, 141.5,
136.5, 134.1, 125.6 (C), 145.0, 135.0, 130.5, 121.2, 112.3, 107.3, 77.7,
52.0 (CH), 63.9, 36.5, 36.1, 34.6, 34.2, 29.8, 29.5 (×4), 29.4, 29.3
(×2), 29.2 (×2), 29.1, 29.0, 28.4, 25.6, 25.3, 24.9, 24.3 (CH2), 61.5,
61.2, 56.2, 56.0 (CH3); IR νmax 3300 br (NH), 1731 br, 1673 (CO)





pentanoate (9): oil; [α]D +5.1 (c 0.3, CHCl3);
1H NMR (500 MHz)
δ 7.44 (1H, s), 7.30 (1H, d, J = 10.8 Hz), 7.20 (1H, br d, J ≈ 7 Hz,
NH), 6.86 (1H, ddd, J = 9.7, 5.5, 2.5 Hz), 6.84 (1H, d, J = 10.8 Hz),
6.53 (1H, s), 5.98 (1H, br d, J ≈ 9.8 Hz), 4.81 (1H, m), 4.65 (1H, m),
4.25 (2H, m), 4.15 (1H, m), 3.96 (3H, s), 3.93 (3H, s), 3.90 (3H, s),
3.67 (1H, m), 3.65 (3H, s), 3.30 (3H, s), 2.50 (1H, br dd, J ≈ 13.7, 6.3
Hz), 2.45−2.20 (9H, br m), 2.00−1.80 (7H, br m), 1.75−1.60 (2H,
m); 13C NMR (125 MHz) δ 179.5, 173.3, 171.9, 164.6, 164.0, 153.5,
152.0, 151.1, 141.7, 136.7, 134.3, 125.6 (C), 145.6, 135.3, 130.8, 121.2,
112.7, 107.4, 75.5, 75.0, 64.1, 52.0 (CH), 61.0, 43.1, 40.4, 36.8, 34.9,
33.6, 32.1, 29.9, 29.7, 20.8 (CH2), 61.5, 61.3, 56.3, 56.1 (×2) (CH3);
IR νmax 3300 br (OH, NH), 1730 br, 1656 (CO) cm−1; HR ESMS




octanoate (10): oil; [α]D −106.6 (c 0.37, CHCl3); 1H NMR (500
MHz) δ 7.38 (1H, s), 7.29 (1H, d, J = 10.7 Hz), 6.89 (1H, ddd, J = 9.7,
5.5, 3 Hz), 6.82 (1H, d, J = 10.7 Hz), 6.54 (1H, s), 6.50 (1H, br d, J ≈
7 Hz, NH), 6.02 (1H, ddd, J = 9.7, 2.5, 1 Hz), 4.80 (1H, m), 4.63 (1H,
m), 4.26 (1H, m), 4.20−4.10 (2H, br m), 3.98 (3H, s), 3.94 (3H, s),
3.89 (3H, s), 3.65 (3H, s), 3.63 (1H, m), 3.37 (3H, s), 2.52 (1H, br dd,
J ≈ 13.7, 6.3 Hz), 2.50−2.20 (5H, br m), 2.00−1.70 (5H, br m), 1.65−
1.40 (10H, br m), 1.35−1.20 (4H, br m); 13C NMR (125 MHz) δ
179.5, 173.7, 172.6, 164.6, 164.0, 153.5, 151.3, 151.2, 141.8, 136.4,
134.1, 125.7 (C), 145.5, 135.1, 130.8, 121.4, 112.3, 107.4, 76.2, 75.1,
64.3, 52.0 (CH), 60.9, 43.1, 40.4, 37.0, 36.2, 34.2, 32.3, 30.1, 29.9, 28.8,
28.6, 25.2, 24.7 (CH2), 61.6, 61.4, 56.8, 56.3, 56.2 (CH3); IR νmax 3300
br (OH, NH), 1724 br, 1673 (CO) cm−1; HR ESMS m/z 740.3649




dodecanoate (11): oil; [α]D −19 (c 0.14, CHCl3); 1H NMR (500
MHz) δ 7.37 (1H, s), 7.28 (1H, d, J = 10.7 Hz), 6.90 (1H, ddd, J = 9.7,
5.5, 2.5 Hz), 6.81 (1H, d, J = 10.7 Hz), 6.53 (1H, s), 6.40 (1H, br d, J
≈ 7 Hz, NH), 6.03 (1H, dt, J = 9.8, 1.5 Hz), 4.77 (1H, m), 4.66 (1H,
m), 4.27 (1H, br t, J ≈ 9.5 Hz), 4.17 (2H, t, J = 6.6 Hz), 3.98 (3H, s),
3.95 (3H, s), 3.91 (3H, s), 3.66 (3H, s), 3.60 (1H, m), 3.37 (3H, s),
3.30 (1H, br s, OH), 2.52 (1H, br dd, J ≈ 13.3, 6.3 Hz), 2.45−2.15
(8H, br m), 2.00 (1H, m), 1.90−1.50 (10H, br m), 1.35−1.20 (12H,
br m); 13C NMR (125 MHz) δ 179.4, 173.8, 172.7, 164.4, 164.0,
153.4, 151.3, 151.2, 141.7, 136.3, 134.1, 125.7 (C), 145.3, 135.1, 130.7,
121.4, 112.3, 107.4, 76.5, 75.0, 64.4, 52.0 (CH), 60.9, 43.0, 39.9, 37.0,
36.4, 34.3, 32.4, 30.0, 29.9, 29.3−29.0 (six partially overlapped signals),
25.3, 24.9 (CH2), 61.5, 61.3, 57.0, 56.3, 56.1 (CH3); IR νmax 3300 br
(OH, NH), 1737 br, 1674 (CO) cm−1; HR ESMS m/z 796.4276




hexadecanoate (12): oil; [α]D −59 (c 0.4, CHCl3); 1H NMR (500
MHz) δ 7.40 (1H, s), 7.29 (1H, d, J = 10.7 Hz), 6.89 (1H, ddd, J = 9.7,
5.4, 3 Hz), 6.82 (1H, d, J = 10.7 Hz), 6.60 (1H, br d, J ≈ 7 Hz, NH),
6.52 (1H, s), 6.02 (1H, ddd, J = 9.7, 2.5, 1.5 Hz), 4.76 (1H, m), 4.66
(1H, m), 4.28 (1H, br t, J ≈ 9.5 Hz), 4.16 (2H, t, J = 6.6 Hz), 3.98
(3H, s), 3.95 (3H, s), 3.90 (3H, s), 3.64 (3H, s), 3.60 (1H, m), 3.37
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(3H, s), 3.30 (1H, br s, OH), 2.52 (1H, br dd, J ≈ 13.3, 6.3 Hz), 2.45−
2.20 (8H, br m), 1.99 (1H, m), 1.85−1.50 (10H, br m), 1.35−1.20
(20H, br m); 13C NMR (125 MHz) δ 179.4, 173.8, 172.7, 164.4,
164.0, 153.4, 151.3, 151.2, 141.7, 136.3, 134.1, 125.7 (C), 145.3, 135.1,
130.7, 121.4, 112.3, 107.4, 76.5, 75.0, 64.4, 52.0 (CH), 60.9, 43.0, 39.9,
37.0, 36.4, 34.3, 32.4, 30.0, 29.9, 29.5−29.0 (10 partially overlapped
signals), 25.4, 24.9 (CH2), 61.5, 61.3, 57.0, 56.3, 56.1 (CH3); IR νmax
3300 br (OH, NH), 1727 br, 1671 (CO) cm−1; HR ESMS m/z
852.4896 (M + H+), calcd for C48H70NO12, 852.4898.
Data for methyl 8-oxo-8-[(7S)-(1,2,3,10-tetramethoxy-9-
oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl)amino]-
octanoate (14): oil; [α]D −119.3 (c 2, CHCl3); 1H NMR (500 MHz)
δ 7.65 (1H, br d, J ≈ 7 Hz, NH), 7.49 (1H, s, H-8), 7.28 (1H, d, J =
10.5 Hz, H-12), 6.83 (1H, d, J = 10.5 Hz, H-11), 6.50 (1H, s, H-4),
4.60 (1H, br dt, J ≈ 11.5, 7 Hz, H-7), 3.96 (3H, s, 10-OMe), 3.90 (3H,
s, 2-OMe), 3.85 (3H, s, 3-OMe), 3.62 (3H, s, 1-OMe), 3.59 (3H, s,
ester OMe), 2.46 (1H, br dd, J ≈ 13.8, 6.5 Hz, H-5α or H-5β), 2.34
(1H, br td, J ≈ 13.5, 6.5 Hz, H-5β or H-5α), 2.30−2.10 (5H, br m, H-
6α or H-6β, H-2′, H-7′), 1.84 (1H, m, H-6α or H-6β), 1.50−1.40 (4H,
br m, H-3′, H-6′), 1.25−1.20 (4H, br m, H-4′, H-5′); 13C NMR (125
MHz) δ 179.5 (C-9), 174.1 (C-8′), 172.7 (C-1′), 163.9 (C-10), 153.4
(C-3), 152.1 (C-7a), 151.1 (C-1), 141.6 (C-2), 136.6 (C-12a), 135.2
(C-12), 134.2 (C-4a), 130.5 (C-8), 125.6 (C-12b), 112.5 (C-11),
107.3 (C-4), 61.5 (1-OMe), 61.2 (2-OMe), 56.3 (10-OMe), 56.0 (3-
OMe), 52.1 (C-7), 51.3 (ester OMe), 36.5 (C-6), 35.8 (C-2′), 33.8
(C-7′), 29.8 (C-5), 28.8, 28.6, 25.1, 24.6 (C-3′ to C-6′); IR νmax 3300
br (NH), 1735 br, 1671, 1654 (CO) cm−1; HR ESMS m/z
528.2599 (M + H+), calcd for C29H38NO8, 528.2597. NMR signals of
this compound were assigned with the aid of 2D homo- and
heteronuclear pulse sequences (COSY, HSQC, HMBC). For atom
numbering see the Supporting Information. Signal assignments within
the colchicine fragment were consistent with literature data for
colchicine.33
Data for methyl 12-oxo-12-[(7S)-(1,2,3,10-tetramethoxy-9-
oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl)amino]-
dodecanoate (15): oil; [α]D −55 (c 0.9, CHCl3); 1H NMR (500
MHz) δ 7.49 (1H, s), 7.48 (1H, br s, NH), 7.29 (1H, d, J = 10.5 Hz),
6.83 (1H, d, J = 10.5 Hz), 6.50 (1H, s), 4.62 (1H, m), 3.98 (3H, s),
3.91 (3H, s), 3.86 (3H, s), 3.62 (3H, s), 3.61 (3H, s), 2.47 (1H, br dd,
J ≈ 13.3, 6.4 Hz), 2.35 (1H, br td, J ≈ 13.3, 6.7 Hz), 2.30−2.10 (5H,
br m), 1.83 (1H, m), 1.60−1.45 (4H, br m), 1.35−1.20 (12H, br m);
13C NMR (125 MHz) δ 179.5, 174.2, 172.7, 163.9, 153.4, 152.1, 151.1,
141.6, 136.6, 134.2, 125.6 (C), 135.2, 130.5, 112.5, 107.3, 52.1 (CH),
36.6, 36.0, 34.0, 29.9, 29.3−29.0 (six partially overlapped signals), 25.3,
24.8 (CH2), 61.5, 61.3, 56.3, 56.0, 51.3 (CH3); IR νmax 3300 br (NH),
1736 br, 1674 (CO) cm−1; HR ESMS m/z 584.3229 (M + H+),
calcd for C33H46NO8, 584.3223.
Data for methyl 16-oxo-16-[(7S)-(1,2,3,10-tetramethoxy-9-
oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl)amino]-
hexadecanoate (16): oil; [α]D −81.1 (c 1.3, CHCl3); 1H NMR (500
MHz) δ 8.00 (1H, br d, J ≈ 6.5 Hz, NH), 7.49 (1H, s), 7.24 (1H, d, J
= 10.7 Hz), 6.80 (1H, d, J = 10.7 Hz), 6.44 (1H, s), 4.56 (1H, m), 3.92
(3H, s), 3.85 (3H, s), 3.80 (3H, s), 3.57 (3H, s), 3.56 (3H, s), 2.40
(1H, br dd, J ≈ 13, 6 Hz), 2.30 (1H, br td, J ≈ 13, 6.4 Hz), 2.20−2.10
(5H, br m), 1.80 (1H, m), 1.55−1.40 (4H, br m), 1.30−1.15 (20H, br
m); 13C NMR (125 MHz) δ 179.2, 174.0, 172.8, 163.7, 153.2, 152.3,
150.9, 141.4, 136.6, 134.1, 125.4 (C), 135.1, 130.4, 112.5, 107.1, 52.0
(CH), 36.2, 35.8, 33.8, 29.7, 29.3−28.8 (10 partially overlapped
signals), 25.2, 24.7 (CH2), 61.3, 61.0, 56.1, 55.8, 51.1 (CH3); IR νmax
3300 br (NH), 1727 br, 1671 (CO) cm−1; HR ESMS m/z 640.3845
(M + H+), calcd for C37H54NO8, 640.3849.
Data for 5-oxo-5-[(7S)-(1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-
tetrahydrobenzo[a]heptalen-7-yl)amino]pentanoic acid (17):
oil; [α]D −110.9 (c 1.1, CHCl3); 1H NMR (500 MHz) δ 8.10 (1H, br
d, J ≈ 6.5 Hz, NH), 7.80 (1H, br s), 7.42 (1H, d, J = 10.8 Hz), 6.97
(1H, d, J = 10.8 Hz), 6.55 (1H, s), 4.65 (1H, m), 4.00 (3H, s), 3.94
(3H, s), 3.90 (3H, s), 3.64 (3H, s), 2.52 (1H, br dd, J ≈ 13.8, 6.4 Hz),
2.45−2.20 (6H, br m), 2.05−1.90 (3H, br m) (carboxyl proton signal
not detected); 13C NMR (125 MHz) δ 179.4, 176.1*, 172.8, 164.0,
153.7, 153.5, 151.2, 141.6, 137.8, 134.4, 125.4 (C), 136.3, 130.9, 114.1,
107.5, 52.8 (CH), 36.0, 34.3, 33.3*, 30.0, 20.8 (CH2), 61.6, 61.3, 56.5,
56.2 (CH3) (asterisked signals are low and broad); IR νmax 3300−2500
br (COOH, NH), 1713 br, 1660 (CO) cm−1; HR ESMS m/z
472.1972 (M + H+), calcd for C25H30NO8, 472.1971.
Data for 8-oxo-8-[(7S)-(1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-
tetrahydrobenzo[a]heptalen-7-yl)amino]octanoic acid (18): oil;
[α]D −105.5 (c 0.48, CHCl3); 1H NMR (500 MHz) δ 7.70 (1H, s),
7.39 (1H, d, J = 10.7 Hz), 6.92 (1H, d, J = 10.7 Hz), 6.85 (1H, br s,
NH), 6.53 (1H, s), 4.70 (1H, m), 4.00 (3H, s), 3.95 (3H, s), 3.91 (3H,
s), 3.65 (3H, s), 2.52 (1H, br dd, J ≈ 13.5, 6.2 Hz), 2.40−2.20 (6H, br
m), 1.86 (1H, m), 1.70−1.55 (4H, br m), 1.35−1.25 (4H, br m)
(carboxyl proton signal not detected); 13C NMR (125 MHz) δ 181.5*,
179.4, 173.5, 163.7, 153.5, 153.3, 151.1, 141.6, 137.4, 134.4, 125.6 (C),
135.3, 130.9, 113.1, 107.4, 52.3 (CH), 36.7*, 36.2, 35.8, 29.9, 28.9,
28.8, 25.5 (×2) (CH2), 61.6, 61.3, 56.4, 56.1 (CH3) (asterisked signals
are low and broad); IR νmax 3300−2600 br (OH, NH), 1714 br, 1652




acid (19): oil; [α]D −93.6 (c 0.7, CHCl3); 1H NMR (500 MHz) δ
7.74 (1H, s), 7.36 (1H, d, J = 10.7 Hz), 6.89 (1H, d, J = 10.7 Hz), 6.87
(1H, br s, NH), 6.54 (1H, s), 4.72 (1H, m), 3.99 (3H, s), 3.95 (3H, s),
3.90 (3H, s), 3.65 (3H, s), 2.51 (1H, br dd, J ≈ 13.6, 6.3 Hz), 2.40−
2.20 (6H, br m), 1.83 (1H, m), 1.65−1.55 (4H, br m), 1.35−1.20
(12H, br m) (carboxyl proton signal not detected); 13C NMR (125
MHz) δ 179.6, 177.5*, 173.2, 163.9, 153.5, 152.3, 151.2, 141.7, 137.0,
134.2, 125.6 (C), 135.5, 130.8, 113.0, 107.5, 52.0 (CH), 37.1, 36.2,
34.0*, 29.9, 29.1, 28.9, 28.7−28.5 (four partially overlapped signals),
25.2, 24.7 (CH2), 61.6, 61.3, 56.3, 56.1 (CH3) (asterisked signals are
low and broad); IR νmax 3300−2600 br (OH, NH), 1729 br, 1652




acid (20): oil; [α]D −68.4 (c 0.12, CHCl3); 1H NMR (500 MHz) δ
7.66 (1H, s), 7.35 (1H, d, J = 10.7 Hz), 6.90 (1H, br s, NH), 6.87 (1H,
d, J = 10.7 Hz), 6.53 (1H, s), 4.71 (1H, m), 3.99 (3H, s), 3.94 (3H, s),
3.90 (3H, s), 3.63 (3H, s), 2.50 (1H, br dd, J ≈ 13.3, 6.1 Hz), 2.37
(1H, br td, J ≈ 13.3, 6.7 Hz), 2.35−2.20 (5H, br m), 1.83 (1H, m),
1.65−1.50 (4H, br m), 1.35−1.20 (20H, br m) (carboxyl proton signal
not detected); 13C NMR (125 MHz) δ 179.6, 177.5*, 173.1, 164.0,
153.5, 152.2, 151.2, 141.7, 136.9, 134.2, 125.6 (C), 135.4, 130.8, 112.9,
107.5, 52.0 (CH), 37.1, 36.3, 34.0*, 29.9, 29.3−28.8 (10 partially
overlapped signals), 25.4, 24.8 (CH2), 61.6, 61.4, 56.4, 56.1 (CH3)
(asterisked signals are low and broad); IR νmax 3300 br (OH, NH),
1717 br, 1653 (CO) cm−1; HR ESMS m/z 626.3696 (M + H+),




heptalen-7-yl)amino}pentanoate (23): oil; [α]D −75.1 (c 0.25,
CHCl3);
1H NMR (500 MHz) δ 7.44 (1H, s), 7.25 (1H, d, J = 10.8
Hz), 7.10 (1H, br s, NH), 6.82 (1H, br dt, J = 9.8, 4.5 Hz), 6.80 (1H,
d, J = 10.8 Hz), 6.48 (1H, s), 5.96 (1H, br d, J ≈ 9.8 Hz), 4.61 (1H,
m), 4.55 (1H, m), 4.10−4.00 (3H, br m), 3.95 (3H, s), 3.90 (3H, s),
3.86 (3H, s), 3.61 (3H, s), 3.33 (1H, m), 3.27 (3H, s), 2.46 (1H, br dd,
J ≈ 13.7, 6.3 Hz), 2.40−2.15 (8H, br m), 2.00−1.50 (9H, br m), 0.85
(9H, s), 0.05 (3H, s), 0.03 (3H, s); 13C NMR (125 MHz) δ 179.4,
173.0, 171.7, 164.2, 163.9, 153.4, 151.9, 151.1, 141.6, 136.6, 134.2,
125.6, 17.9 (C), 145.3, 135.1, 130.8, 121.3, 112.5, 107.3, 74.7, 74.5,
65.8, 52.1 (CH), 60.9, 43.1, 42.9, 36.7, 34.9, 33.4, 32.6, 29.9, 29.8, 20.6
(CH2), 61.5, 61.3, 56.3, 56.1, 56.0, 25.8 (×3), −4.4, −4.6 (CH3); IR
νmax 3300 br (NH), 1731 br, 1674 (CO) cm−1; HR ESMS m/z




heptalen-7-yl)amino}octanoate (24): oil; [α]D −87.2 (c 0.74,
CHCl3);
1H NMR (500 MHz) δ 7.39 (1H, s), 7.28 (1H, d, J = 10.8
Hz), 6.89 (1H, dt, J = 9.8, 4 Hz), 6.80 (1H, d, J = 10.8 Hz), 6.53 (1H,
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s), 6.50 (1H, br d, J ≈ 7 Hz, NH), 6.02 (1H, br d, J ≈ 9.8 Hz), 4.70−
4.55 (2H, m), 4.20−4.05 (3H, br m), 3.98 (3H, s), 3.94 (3H, s), 3.90
(3H, s), 3.65 (3H, s), 3.40 (1H, m), 3.31 (3H, s), 2.52 (1H, br dd, J ≈
13.7, 6.3 Hz), 2.41 (1H, br td, J ≈ 13.2, 6.8 Hz), 2.35−2.20 (5H, br
m), 2.00 (1H, m), 1.90−1.50 (12H, br m), 1.35−1.20 (4H, br m), 0.88
(9H, s), 0.07 (3H, s), 0.05 (3H, s); 13C NMR (125 MHz) δ 179.4,
173.6, 172.5, 164.3, 164.0, 153.4, 151.3, 151.1, 141.8, 136.3, 134.1,
125.7, 18.0 (C), 145.3, 135.1, 130.8, 121.5, 112.2, 107.4, 74.9, 74.6,
65.9, 52.0 (CH), 60.8, 43.3, 43.2, 37.0, 36.3, 34.2, 32.7, 30.0, 29.9, 28.8,
28.7, 25.2, 24.7 (CH2), 61.6, 61.4, 56.3, 56.2, 56.1, 25.9 (×3), −4.3,
−4.6 (CH3); IR νmax 3300 br (NH), 1731 br, 1674 (CO) cm−1; HR




[a]heptalen-7-yl)amino}dodecanoate (25): oil; [α]D −72.8 (c 1.1,
CHCl3);
1H NMR (500 MHz) δ 7.44 (1H, s, H-8), 7.29 (1H, d, J =
10.7 Hz, H-12), 6.90 (1H, br d, J ≈ 7.5 Hz, NH), 6.88 (1H,
overlapped m, H-3′), 6.82 (1H, d, J = 10.7 Hz, H-11), 6.52 (1H, s, H-
4), 6.00 (1H, dt, J = 9.8, 1.5 Hz, H-2′), 4.65 (1H, m, H-7), 4.57 (1H,
m, H-5′), 4.15−4.05 (3H, br m, H-7′, H-11′), 3.98 (3H, s, OMe), 3.94
(3H, s, OMe), 3.89 (3H, s, OMe), 3.65 (3H, s, OMe), 3.40 (1H, m, H-
9′), 3.30 (3H, s, 9′-OMe), 2.50 (1H, br dd, J ≈ 13.3, 6 Hz, H-5α or H-
5β), 2.38 (1H, br td, J ≈ 13.2, 6.8 Hz, H-5β or H-5α), 2.35−2.15 (7H,
br m, H-6α or H-6β, H-4′, H-13′, H-22′), 2.00 (1H, ddd, J = 14, 9.3,
3.5 Hz, H-6β or H-6α), 1.80−1.50 (10H, br m, H-6′, H-8′, H-10′, H-
14′, H-21′), 1.35−1.20 (12H, br m, H-15′ to H-20′), 0.86 (9H, s,
tBuSi), 0.07 (3H, s, MeSi), 0.05 (3H, s, MeSi); 13C NMR (125 MHz)
δ 179.4 (C-9), 173.6 (C-12′), 172.7 (C-23′), 164.1 (C-1′), 163.9 (C-
10), 153.4 (C-3), 151.8 (C-7a), 151.1 (C-1), 145.1 (C-3′), 141.6 (C-
2), 136.4 (C-12a), 135.1 (C-12), 134.1 (C-4a), 130.6 (C-8), 125.7 (C-
12b), 121.4 (C-2′), 112.4 (C-11), 107.3 (C-4), 74.8 (C-9′), 74.4 (C-
5′), 65.9 (C-7′), 60.7 (C-11′), 61.5, 61.3, 56.3, 56.1 (×2) (ﬁve OMe
groups), 52.0 (C-7), 43.3, 43.1 (C-6′, H-8′), 34.2 (C-10′), 36.7, 36.1,
32.6 (C-6, C-13′, C-22′), 29.9 (C-5), 29.3−29.0 (seven partially
overlapped signals), 25.3, 24.8 (all remaining methylene groups), 25.8
(×3) (Me3CSi), 17.9 (Me3CSi), −4.4, −4.5 (SiMe2); IR νmax 3300 br
(NH), 1732 br, 1674 (CO) cm−1; HR ESMS m/z 910.5111 (M +
H+), calcd for C50H76NO12Si, 910.5117. NMR signals of this
compound were assigned with the aid of 2D homo- and heteronuclear
pulse sequences (COSY, HSQC, HMBC). For atom numbering see
the Supporting Information. Signal assignments within the colchicine




[a]heptalen-7-yl)amino}hexadecanoate (26): oil; [α]D −73.4 (c
0.84, CHCl3);
1H NMR (500 MHz) δ 7.42 (1H, s), 7.29 (1H, d, J =
10.7 Hz), 6.88 (1H, dt, J = 9.8, 4.5 Hz), 6.82 (1H, d, J = 10.7 Hz), 6.78
(1H, br d, J ≈ 7 Hz, NH), 6.51 (1H, s), 6.01 (1H, dt, J = 9.8, 1.5 Hz),
4.65 (1H, m), 4.58 (1H, m), 4.20−4.05 (3H, br m), 3.98 (3H, s), 3.94
(3H, s), 3.89 (3H, s), 3.65 (3H, s), 3.40 (1H, m), 3.30 (3H, s), 2.50
(1H, br dd, J ≈ 13.3, 6 Hz), 2.39 (1H, br td, J ≈ 13.2, 6.8 Hz), 2.35−
2.15 (7H, br m), 2.00 (1H, ddd, J = 14, 9.3, 3.5 Hz), 1.85−1.50 (10H,
br m), 1.35−1.20 (20H, br m), 0.87 (9H, s), 0.09 (3H, s), 0.06 (3H,
s); 13C NMR (125 MHz) δ 179.4, 173.8, 172.7, 164.2, 164.0, 153.4,
151.5, 151.3, 141.7, 136.4, 134.2, 125.7, 18.0 (C), 145.1, 135.1, 130.7,
121.5, 112.3, 107.4, 74.9, 74.5, 65.9, 52.0 (CH), 60.8, 43.4, 43.2, 36.9,
36.4, 34.3, 32.7, 30.0, 29.9, 29.6−29.2 (10 partially overlapped signals),
25.4, 25.0 (CH2), 61.6, 61.4, 56.3, 56.2, 56.1, 25.9 (×3), −4.3, −4.4
(CH3); IR νmax 3300 br (NH), 1733 br, 1675 (CO) cm−1; HR
ESMS m/z 966.5756 (M + H+), calcd for C54H84NO12Si, 966.5763.
Biological Methods. Cell Culture. Cell culture media were
purchased from Gibco (Grand Island, NY). Fetal bovine serum
(FBS) was a product of Harlan-Seralab (Belton, U.K.). Supplements
and other chemicals not listed in this section were obtained from
Sigma Chemical Co. (St. Louis, MO). Plastics for cell culture were
supplied by Thermo Scientiﬁc BioLite. All tested compounds were
dissolved in DMSO at a concentration of 10 μg/mL and stored at −20
°C until use.
HT-29, MCF-7, and HEK-293 cell lines were maintained in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) containing glucose (1
g/L), glutamine (2 mM), penicillin (50 IU/mL), streptomycin (50
μg/mL), and amphoterycin (1.25 μg/mL), supplemented with 10%
FBS.
Human A-549 non-small-cell lung carcinoma cells were cultured in
RPMI 1640 supplemented with 10% fetal calf serum (FCS), glutamine,
and antibiotics as previously described.30 Human ovarian carcinomas
A2780 and A2780AD (MDR (multidrug resistance) overexpressing P-
glycoprotein) cell lines were cultured as above with the addition of
0.25 unit/mL bovine insulin.
Cytotoxicity Assays, Indirect Immunoﬂuorescence, and Cell
Cycle. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT; Sigma Chemical Co.) dye reduction assay in 96-well
microplates was used, as previously described.34 A total of 5 × 103 HT-
29, MCF-7, or HEK-293 cells in a total volume of 100 μL of their
respective growth media were incubated with serial dilutions of the
tested compounds. After 3 days of incubation (37 °C, 5% CO2 in a
humid atmosphere), 10 μL of MTT (5 mg/mL in phophate-buﬀered
saline (PBS)) was added to each well, and the plate was incubated for
a further 4 h (37 °C). The resulting formazan was dissolved in 150 μL
of 0.04 N HCl/2-propanol and read at 550 nm. All determinations
were carried out in triplicate.
Cytotoxic evaluation on A2780 and A2780AD cells was performed
with the MTT assay modiﬁed as previously described.35 Indirect
immunoﬂuorescence was performed in A549 cells that had been
cultured overnight in 12 mm round coverslips and incubated for a
further 24 h in the absence (drug vehicle DMSO) or in the presence of
diﬀerent ligand concentrations. Attached cells were permeabilized with
Triton X100 and ﬁxed with 3.7% formaldehyde. Microtubules were
speciﬁcally stained with DM1A α-tubulin monoclonal antibodies, and
DNA was stained with Hoechst 33342 as previously described.36 The
preparations were examined using a Zeiss axioplan epiﬂuorescence
microscope, and the images were recorded with a Hamamatsu 4742-95
cooled charge-coupled device (CCD) camera. Progression through the
cell cycle analysis was assessed by ﬂow cytometry DNA determination
with propidium iodide. Cells were ﬁxed, treated with RNase, and
stained with propidium iodide as previously described.37 Analysis was
performed with a Coulter Epics XL ﬂow cytometer.
Tubulin Assembly Inhibition Assay. The eﬀect of the compounds
on the assembly of puriﬁed tubulin (Table 3) was determined by
incubating 20 μM puriﬁed tubulin at 37 °C for 30 min in GAB (3.4 M
glycerol, 10 mM sodium phospate, 1 mM EGTA, 1 mM GTP, pH 6.5)
in the presence of 25 μM pironetin, colchicine, and docetaxel (a
microtubule-stabilizing ligand as a positive control) and a 30 μM
concentration each of compounds 1, 3, 9, and 11 or 2 μL of DMSO
(vehicle). The samples were processed, and the critical concentration
for tubulin assembly29 in the presence of the ligands was calculated as
described.38 The results of Table 4 were obtained with the same
methodology except for the changes in ligand concentrations. The
numerical data mentioned in the tables represent average values of ﬁve
measurements. Errors are standard errors of the average.
Interaction of Compounds with Tubulin at Equimolecular
Concentration. A 30 μM ﬁnal solution each of compounds 1, 3, 9,
and 11 (previously dissolved at 10 mM in dimethyl sulfoxide) in a
buﬀer mixture (10 mM sodium phosphate, 30% glycerol, 1 mM
EGTA, 1 mM GTP, 6 mM MgCl2) was mixed with a 30 μM ﬁnal
solution of tubulin in the same buﬀer. The mixture was allowed to
stand for 1 h at 37 °C and extracted with dichloromethane. This
yielded solution A, which was analyzed for its content in the respective
ligand.
A 30 μM ﬁnal solution each of compounds 1, 3, 9, and 11
(previously dissolved at 10 mM in dimethyl sulfoxide) in a buﬀer
mixture (10 mM sodium phosphate, 30% glycerol, 1 mM EGTA, 1
mM GTP, 6 mM MgCl2) was mixed with a 30 μM ﬁnal solution of
tubulin in the same buﬀer. The mixture was allowed to stand for 1 h at
37 °C to allow for the formation of microtubules and then
ultracentrifuged. The supernatant solution and the solid pellet were
then separated and extracted with dichloromethane. This yielded
Journal of Medicinal Chemistry Article
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solutions B and C, respectively, which were analyzed for their content
in the respective ligand.
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Politećnico Nacional, Mexico, for kindly sending the pironetin
samples, P. Lastres for his help with ﬂow cytometry, and the
Matadero Municipal Vicente de Lucas in Segovia for providing
the calf brains which were the source of tubulin.
■ ABBREVIATIONS USED
TBMs, tubulin-binding molecules; NMM, N-methylmorpho-
line; HT-29, human colon adenocarcinoma cells; MCF-7,
breast adenocarcinoma cells; HEK-293, human embryonic
kidney cells; A2780, ovarian carcinoma cells sensitive to
chemotherapy; A2780AD, ovarian carcinoma cells resistant to
chemotherapy
■ REFERENCES
(1) Garcia, M.; Jemal, A.; Ward, E. M.; Center, M. M.; Hao, Y.;
Siegel, R. L.; Thun, M. J. Global Cancer Facts & Figures 2007;
American Cancer Society: Atlanta, GA, 2007.
(2) (a) Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell
2000, 100, 57−70. (b) Stratton, M. R.; Campbell, P. J.; Futreal, P. A.
The cancer genome. Nature 2009, 458, 719−724. (c) Hanahan, D.;
Weinberg, R. A. The hallmarks of cancer: the next generation. Cell
2011, 144, 646−674.
(3) (a) Boyle, F. T.; Costello, G. F. Cancer therapy: a move to the
molecular level. Chem. Soc. Rev. 1998, 27, 251−261. (b) Gibbs, J. B.
Mechanism-based target identification and drug discovery in cancer
research. Science 2000, 287, 1969−1973.
(4) (a) Penn, L. Z. Apoptosis modulators as cancer therapeutics.
Curr. Opin. Invest. Drugs 2001, 2, 684−692. (b) Zhou, B.; Liu, Z.-L.
Bioantioxidants: from chemistry to biology. Pure Appl. Chem. 2005, 77,
1887−1903. (c) Park, H.-J.; Jung, H.-J.; Lee, K.-T.; Choi, J. Biological
characterization of the chemical structures of naturally occurring
substances with cytotoxicity. Nat. Prod. Sci. 2006, 12, 175−192.
(d) Portt, L.; Norman, G.; Clapp, C.; Greenwood, M.; Greenwood, M.
T. Anti-apoptosis and cell survival: a review. Biochim. Biophys. Acta,
Mol. Cell Res. 2011, 1813, 238−259. (e) Torres-Andoń, F.; Fadeel, B.
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